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Abstract
 
B cell–derived chronic lymphocytic leukemia (B-CLL) represents a common malignancy
whose cell derivation and pathogenesis are unknown. Recent studies have shown that 
 
 
 
50%
of CLLs display hypermutated immunoglobulin variable region (IgV) sequences and a more fa-
vorable prognosis, suggesting that they may represent a distinct subset of CLLs which have
transited through germinal centers (GCs), the physiologic site of IgV hypermutation. To fur-
ther investigate the phenotype of CLLs, their cellular derivation and their relationship to nor-
mal B cells, we have analyzed their gene expression profiles using oligonucleotide-based DNA
chip microarrays representative of 
 
 
 
12,000 genes. The results show that CLLs display a com-
mon and characteristic gene expression profile that is largely independent of their IgV geno-
type. Nevertheless, a restricted number of genes (
 
 
 
30) have been identified whose differential
expression can distinguish IgV mutated versus unmutated cases and identify them in indepen-
dent panels of cases. Comparison of CLL profiles with those of purified normal B cell subpop-
ulations indicates that the common CLL profile is more related to memory B cells than to those
derived from naive B cells, CD5
 
 
 
 B cells, and GC centroblasts and centrocytes. Finally, this
analysis has identified a subset of genes specifically expressed by CLL cells of potential pathoge-
netic and clinical relevance.
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Introduction
 
B cell chronic lymphocytic leukemia (B-CLL)
 
*
 
 represents
the most common leukemia in the Western countries with
an estimated incidence of 1 per 100,000 per y (1). This
disease is characterized by the monoclonal expansion of B
lymphocytes in the peripheral blood, bone marrow, and
lymphoid organs, and by an indolent course which ulti-
mately becomes aggressive and invariably lethal (1). Cur-
rent knowledge of the pathogenesis of CLL is limited be-
cause no specific genetic alteration has yet been associated
with this disease. In particular, CLL is not associated
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with reciprocal balanced chromosomal translocations, but
rather with specific deletions (2) suggesting the loss of
presently unidentified tumor suppressor genes. CLL cells
have a low proliferative rate and a prolonged life span,
suggesting that their primary alteration may be a defect in
apoptosis (1).
The cellular origin of CLL is unknown and has been the
object of recent controversy. CLL cells are characterized by
the expression of the cell surface markers CD5, CD23,
CD19, and low levels of sIgM/IgD, a pattern not shared by
any known B cell subpopulation (1, 3). The expression of
the CD5 antigen was originally taken to suggest that
B-CLL originates from CD5
 
 
 
 B cells (4), which are usually
characterized by unmutated Ig variable region (IgV) genes
(5, 6). However, recent studies have shown that 50–70% of
CLL have undergone IgV hypermutation (7–9), a phe-
nomenon that characterizes normal B cells undergoing a T
cell–dependent germinal center (GC) reaction (10) and
malignant B cells derived from GC or post-GC B cells (11,
12). This finding has led to the hypothesis that CLL cases
displaying mutated IgV may derive from a cell that had
transited through the GC, whereas those with germline
IgV may derive from GC-independent cells (8, 9, 13). This
hypothesis has both biological and clinical relevance
since  the two subgroups have different prognosis, with
IgV-mutated CLL (M-CLL) displaying a more benign clin-
ical course (13, 14).
To further investigate the phenotype of CLL subtypes,
their cellular derivation and their relationship with normal
B cells, we have analyzed their gene expression profiles us-
ing oligonucleotide-based DNA chip microarrays (Affyme-
trix) representative of 
 
 
 
12,000 genes. The gene expression
profiles have been comparatively analyzed: (i) between
M-CLL and IgV-unmutated CLL (UM-CLL) cases, to de-
termine whether the two subgroups are different; (ii) with
those of normal B cell subpopulations, including GC-inde-
pendent (CD5
 
 
 
), preGC (naive), GC (centroblasts [CBs]
and centrocytes [CCs]), and post-GC (memory) B cells, to
investigate their cellular derivation; and (iii) with those of
normal B cell subpopulations and of other malignancies de-
rived from mature B cells to identify genes that are specifi-
cally expressed in CLL.
 
Materials and Methods
 
CLL Cases.
 
Peripheral blood from CLL patients who had
not received treatment was taken after informed consent. CLL
cells were enriched from PBMCs by magnetic cell separation us-
ing the MidiMACS
 
®
 
 system (Miltenyi Biotec). After Ficoll-Iso-
paque™ density centrifugation, PBMCs were incubated with
CD19-microbeads (MB) (Miltenyi Biotec). Magnetically labeled
cells were isolated by passing the cell suspension over an LS col-
umn (Miltenyi Biotec). All isolation steps were performed on ice
and using ice-cold solutions. Sequences of IgV
 
H
 
 genes of the 34
CLL cases were determined as described previously (15).
 
Isolation of Normal Human B Cell Subsets and Tumor Cells.
 
A
detailed description of the gene expression profiles of normal B
cell subpopulations, including the methods for purification and
characterization, will be reported elsewhere (unpublished data).
Briefly, tonsils were obtained from routine tonsillectomies per-
formed at the Children’s Hospital of Columbia University. The
specimens were kept on ice immediately after surgical removal,
and all cell isolation steps were performed on ice. B cell subsets
were isolated by magnetic cell separation (see above). The isola-
tion strategies were based on recent characterizations of the hu-
man B cell subsets (16–19). For the isolation of naive B cells, ton-
sillar mononuclear cells were first incubated with anti-CD27,
anti-CD10 (both BD PharMingen), and anti-CD3 (Beckman
Coulter/Immunotech), then with anti–IgG
 
1
 
-MB and anti–
CD14-MB. Magnetically labeled cells were depleted by passing
the cell suspension over a LD-column (Miltenyi Biotec). The
flow-through was incubated first with anti–IgD-FITC (BD
PharMingen), then with anti–FITC-MB. IgD-positive B cells
were isolated using LS columns. CBs were isolated in a single step
by staining tonsillar mononuclear cells with anti-CD77 (Beckman
Coulter/Immunotech), followed by incubation with mouse anti–
rat IgM (BD PharMingen), and finally anti–IgG
 
1
 
-MB. The cells
were passed over a LS column. CC: tonsillar MC were first incu-
bated with anti-CD77, then with anti-CD39 (Beckman Coulter/
Immunotech), anti-CD3, and mouse anti–rat IgM, followed by
anti–IgG
 
1
 
-MB staining. The cells were passed subsequently over
a LS column with G21 needle and a LD column. The resulting
flow-through was first incubated with anti-CD10, then with
anti–IgG
 
1
 
-MB. CD10
 
 
 
 CCs were isolated using LS columns.
Memory B cells: tonsillar mononuclear cells were incubated first
with anti-CD10, anti-CD3, and anti-CD38 (BD PharMingen),
the latter at a titer of 1:1,000 to facilitate a selective depletion of
CD38
 
high
 
 plasma cells and GC B cells, then with anti–IgG
 
1
 
-MB
and anti–CD14-MB. Labeled cells were depleted using a LD col-
umn. The flow-through was first stained with anti–CD27-FITC,
then with anti–FITC-MB. CD27
 
 
 
 cells were isolated using a LS
column.
Cord blood was obtained after informed consent. Cord blood
B cells almost exclusively consist of CD5
 
 
 
 B cells. To enrich for
CD5
 
 
 
 B cells from cord blood, mononuclear cells obtained by
Ficoll-Isopaque™ density centrifugation were incubated with
CD19-MB (Miltenyi Biotec). The stained cells were passed over
a LS column.
Follicular lymphoma (FL) cells were isolated from single cell
suspensions from digested lymph nodes or spleen which were his-
tologically involved with FL. These cell suspensions were de-
pleted of T cells, monocytes, NK cells using anti-CD4, -CD8,
-CD14, and -CD56, followed by immunomagnetic beads as de-
scribed previously (20). FL cells were isolated from six individuals
with relapsed FL who had not received any therapy for at least 6
mo before biopsy. Diffuse large cell lymphoma (DLCL) and Bur-
kitt lymphoma (BL) tumor cells were enriched by magnetically
depleting CD3-, CD4-, CD8-, CD14-, CD15-, CD16-, CD56-,
and glycophorin-expressing nontumor cells. All samples were ob-
tained according to appropriate Human Protection Committee
validation and informed patient consent.
 
Generation of cRNA and Microarray Hybridization.
 
Total RNA
was isolated in two steps using Trizol (Life Technologies), fol-
lowed by RNeasy (QIAGEN) purification. Double strand cDNA
was generated from 5 
 
 
 
g of total RNA using a poly dT oligonu-
cleotide that contains a T7 RNA polymerase initiation site and
the SuperScript Choice System kit (Life Technologies). cDNA
was phenol/chloroform extracted. Biotinylated cRNA was gen-
erated by in vitro transcription using the Bio Array™ High
Yield™ RNA Transcript Labeling kit (ENZO Diagnostics, Inc.).
The cRNA was purified using RNeasy. cRNA was fragmented
according to the Affymetrix protocol, and 15 
 
 
 
g of biotinylated 
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cRNA were hybridized to U95A microarrays (Affymetrix). After
scanning (scanner from Affymetrix), the expression values for the
genes were determined using Affymetrix GENECHIP software,
using the Global Scaling option that allows a number of experi-
ments to be normalized to one target intensity, thus facilitating
comparison between multiple experiments.
 
Data Processing.
 
The Affymetrix expression data (average dif-
ferences) was processed as follows. The small and negative expres-
sion levels were clipped-off to be equal to a cutoff value arbi-
trarily chosen as 20. The logarithm of this clipped-off data was
subsequently used throughout analyses.
 
Dendrogram.
 
The hierarchical clustering algorithm used to
generate the dendrogram is based on the average-linkage method
(21, 22). To construct the dendrogram, a subset of genes was used
out of the total of 12588 gene segments present on the microar-
ray, whose expression levels vary the most among the 40 samples,
and which are thus most informative. For the hierarchical cluster-
ing shown in Fig. 1, only genes were chosen whose average
change in expression level from the mean across the whole panel
was at least twofold (2,337 genes selected). Independent analyses
were performed using all genes and only gene segments whose
average change in expression level was at least threefold and four-
fold, respectively. The expression values of each selected gene is
normalized to have 0 mean and unit SD. The distance between
two individual samples is calculated by Euclidean distance with
the normalized expression values.
 
Analysis of Gene Expression Profiles.
 
We used the Genes@
Work software platform which is a gene expression analysis tool
based on the pattern discovery algorithm structural pattern local-
ization analysis by sequential histograms (SPLASH; references 23
and 24). Genes@Work is used here to perform both supervised
and unsupervised gene expression analysis.
Rather than inferring clusters by comparing the gene expres-
sion values of each possible pair of experiments, as it is the case
for the average-linkage method (21, 22), Genes@Work proceeds
by discovering one or more global gene expression “signatures”
that are common to an entire set of at least 
 
n
 
 experiments (the
support experiments), where 
 
n
 
 is a user-selectable parameter
called the minimum support. A Genes@Work pattern represents
(a subset of) the genes that are differentially expressed in (a subset
of) the phenotype set with respect to the control set. A
Genes@Work pattern can be represented as a matrix composed
of columns for the experiments of the phenotype and control set
and rows for the differentially expressed genes (see description of
matrices). The number of experiments in the Genes@Work pat-
tern, 
 
n
 
 
 
 
 
 
 
 
 
n
 
, is called the pattern support. Differential expression
is determined as follows: independently for each gene, an ex-
pected gene expression probability density 
 
p(e)
 
 is computed em-
pirically from the experimental set (the method differs in the case
of supervised versus unsupervised clustering; see below). Then,
given the group of 
 
n
 
 cells, the algorithm builds a cluster with all
of the genes such that the integral of their 
 
p(e)
 
 over the expres-
sion range of the group is less than a predefined threshold 
 
 
 
. The
statistical significance of a Genes@Work pattern is computed
based on the probability of observing a similar pattern (i.e. a pat-
tern with the same number of support experiments and support
genes) in a set of random cells whose genes are distributed ac-
cording to the empirical probability density 
 
p(e)
 
, the null hypoth-
esis (24). Genes@Work patterns are then ranked according to
their statistical significance.
 
Supervised versus Unsupervised Clustering.
 
In supervised cluster-
ing, a phenotype set and a control set is defined. The aim is to
identify a set of genes that optimally discriminate between pheno-
 
type and control sets. The expression probability density 
 
p(e)
 
 is
determined independently for each gene as the one most likely to
produce the expression values observed in the control set, given
the expected error in the measure. This is accomplished by con-
volving the expression values in the control set with a gaussian
kernel, with a SD equal to the error determined from repeatabil-
ity experiments as a function of the expression level (for a review,
see reference 24). The algorithm is run twice, with either set cho-
sen in turn as phenotype, and the resulting gene expression pat-
terns are then fused into a single one.
In unsupervised clustering, a control set is not available as the
algorithm is applied to determine the most likely subsets without
any a-priori knowledge. In this case the expression probability
density is computed differently (24) either as a uniform probabil-
ity density over the expected expression range of the full set, or as
a normal distribution. The latter is used with a mean equal to the
gene expression over the full experimental set and a SD equal to
1/4 of the experimental one.
 
Pattern Discovery.
 
Unsupervised clustering: following compu-
tation of the expression probability of each gene, pattern discov-
ery is performed starting with a support value 
 
n
 
 
 
 
 
 
 
n
 
0
 
 
 
 
 
 
 
m
 
, where
 
n
 
0
 
 is equal to the number of experiments in the set and 
 
m
 
 is the
size of the smallest subset which is expected to be characterized
by a discernible subphenotype (typically, 
 
m
 
 
 
 
 
 
 
n
 
0
 
/4). For a given
support 
 
n
 
, the pattern 
 
z
 
 score 
 
z
 
p
 
(
 
p
 
i
 
,
 
n
 
) of each discovered pattern,
 
p
 
i
 
, is computed. (The pattern 
 
z
 
 score 
 
z
 
p
 
, is inversely related to the
pattern 
 
p
 
 value; when 
 
z
 
p
 
 is sufficiently large, this relation is
 
  
 
p
 
 
 
 
 
1/
 
z
 
p
 
2
 
). The pattern 
 
P
 
(
 
n
 
), corresponding to the maximum pattern
 
z
 
 score 
 
Z
 
p
 
(
 
n
 
), is selected. 
 
Z
 
p
 
(
 
n
 
) 
 
 
 
 1 if no patterns are found for
the given support value. This process is repeated iteratively for
decreasing values of 
 
n
 
, until a sudden increase in the pattern 
 
z
 
score is detected. This corresponds to a maximum of the first de-
rivative of the pattern 
 
z
 
 score function for a support value equal
to 
 
n
 
. Such extrema can be determined, as a first approximation,
when the following condition is satisfied: 
 
Z
 
p
 
(
 
n
 
 – 1)/
 
Z
 
p
 
(
 
n
 
) 
 
 
 
Z
 
p
 
(
 
n
 
)/
 
Z
 
p
 
(
 
n
 
 
 
 1). The pattern P(n) for the corresponding value of
n is called the interest pattern. The experiments that support the
interest pattern become a subset and the genes that support the
interest pattern become the subset-signature. For a discussion of
the pattern z score, see reference 24.
Supervised clustering: the gene expression probability densities
are computed and pattern discovery is performed iteratively with
a decreasing value of the support, starting at N (the size of the
phenotype group), until either a significant gene cluster size is
obtained, or discovered patterns appear to be no longer statisti-
cally significant.
For the unsupervised clustering analysis, an optimal value for
    0.1, or 10% of the total probability, is chosen. For supervised
clustering, due to the significantly higher sensitivity, a smaller
value of     0.01, or 1% of the total probability, is used.
Graphic Representations of Gene Expression Patterns (Matrices).
Columns represent individual experiments, and rows represent
individual genes present on the expression microarray. To gener-
ate a pseudocolor map, first a gene- and experiment-specific
change of variables, from the original measurement v into  ge, is
computed using the formula: 
(1)
where  P and  P are respectively the mean and SD computed
from the gene expression values for that gene in the phenotype
group, and  c and  c are their corresponding values computed
from the control group (Eq. 1). The value of this function is then
ζge
v µp µc + () – 2 ⁄
σp σc + () 2 ⁄
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plotted using a pseudocolor map that represents  ge   0 as black,
 ge   0 as progressively brighter hues of red, and  ge   0 as pro-
gressively brighter levels of green.  ge   4 and  ge    4 corre-
spond to complete saturation of the red and the green, respec-
tively. The resulting pseudocolor map associates the same colors
to measurements that are off by the same number of SDs from
their expected value.
For each gene, the statistical significance of the differential ex-
pression across the phenotype and control sets (gene z score, zg),
is computed using the formula (Eq. 2)
(2)
In contrast to the generally used fold-ratio ( P/ C) to describe
gene expression changes among cell subsets, zg represents the dif-
ferential expression between phenotype and control samples rela-
tive to the variability of their expression levels. Rows are divided
into two groups. First, the genes that are overexpressed in the
first experiment set are reported by decreasing value of the zg
score (most significant first). Then, the genes that are underex-
pressed are reported, ordered by increasing value of the zg score
(most significant first).
Classifier and Classification Method. The classifier is a scoring
function based on the values of a set of genes (gene cluster)
which are differentially expressed in two sets of cell types and can
thus be used for cell type classification. The higher the score, the
more likely it is that a cell type is related to the phenotype set.
Pattern discovery methods are used here to identify gene clusters.
The union of the genes of all statistically significant patterns is
used to define the classifier (see above for pattern discovery
method). Given a set of genes, the scoring function is defined
quantitatively as:
(3)
where f(x)   max ( 1, min (1, x)), nc is the number of genes in
the classifier, and i   1, 2, ...,nc is the label for each individual gene
in the classifier,  i is the expression level of gene i for the new cell,
 i
(1) and  i
(2) represent the mean expression levels of gene i for
cells in the phenotype and control set, respectively (Eq. 3).
Online Supplemental Material. GenBank accession no., Af-
fymetrix entry numbers, and the normalized primary data of the
genes shown in Figs. 2, 4, and 5 are available at the journal’s
website.
Results
A panel of 34 CLLs, characterized for their typical cell
surface phenotype and presence or absence of IgV muta-
tions, was used for this study. From 20 of these samples, tu-
mor cells were purified by magnetic cell separation of
CD19  cells, while 14 cases that showed a representation
of  80% of malignant cells in the peripheral blood were
used as unpurified cell populations (Table I). As in previous
reports (13, 14), CLLs with  2% basepair difference to the
corresponding germline IgV gene were considered as UM-
CLLs. 18 of 34 cases, comparably distributed between puri-
fied and nonpurified samples (11 and 7, respectively), were
shown to be M-CLL carrying 6–33 mutations per case.
zg
µP µC –
σP σC +
-------------------. =
R1
1
nc
---- f
vi µi
1 〈〉 µi
2 〈〉 + – () + 2 ⁄
µi
1 〈〉 µi
2 〈〉 – () 2 ⁄
----------------------------------------------------






i 1 =
nc
∑ =
RNA extracted from these cases was converted into la-
beled cRNA and hybridized to U95A Affymetrix Gene
Chips representative of  12,000 genes, including mostly
known genes ( 80%). Gene expression profiles were ana-
lyzed using two main approaches: (i) unsupervised cluster-
ing, which can identify distinct cell types (e.g., CLL cases)
which have not been classified a-priori; and (ii) supervised
clustering, which allows the identification of differentially
expressed genes between cell types (CLL cases) defined
a-priori according to a given criterium (e.g., presence of
IgV mutations). Unsupervised and supervised clustering were
obtained using two algorithms, the average-linkage method
(21, 22) or the pattern discovery algorithm SPLASH used
by the Genes@Work software platform (see Materials and
Methods; references 23 and 24). The latter is capable of
capturing subtle differences in gene expression by combin-
ing an optimal nonlinear transformation of the gene ex-
pression values coupled with an analytical method to com-
Table I. Summary of the Analysis of CLL Cases for the Level of 
Somatic Hypermutation in Rearranged IgVH Genes
Nonpurified CLLs Purified CLLs
Case VH gene Mutations Case VH gene Mutations
CLL0004 3-23 0 CLL1215 4-34 15
CLL0014 4-39 0 CLL1263 4-34 15
CLL1208 4-61 33a CLL1268 1-69 0
CLL1255 4-34 15 CLL1285 1-69 0
CLL1259 3-9 16 CLL1291 4-59 26
CLL1269 3-23 0 CLL1297 4-59 9
CLL1270 4-34 7 CLL1302 3-73 0
CLL1272 3-23 7 CLL1304 3-15-rel.b 2
CLL1275 3-30 0 CLLB2 3-64/4-34 29/16
CLL1282 3-30 0 CLLB3 1-2 0
CLL1310 3-43 0 CLLB4 1-2 0
CLL1318 3-7 1 CLLB6 1-3/4-59 10/17
CLL1332 4-34 20 CLLB7 BF2P2c 0
CLL1333 4-39 31 CLLB8 1-18 12
CLLB9 3-48 19
CLLB10 3-21 6
CLLB12 3-30 17
CLLB13 5-51 11
CLLB14 3-21 0
CLLB15 1-2 0
Nonpurified CLLs comprised 80% or more tumor cells among PBMCs;
purified CLLs were isolated from PBMCs by magnetic cell separation of
CD19+ cells. If possible, the VH gene nomenclature of Matsuda et al. was
used (reference 56).
aContains a 1-bp insertion.
bGenBank accession no. M99406 (3–15-related rearranged IgV gene).
cVH3-family member.1629 Klein et al.
pute the statistical significance of the identified clusters (see
Materials and Methods and below).
CLLs Display a Common Gene Expression Profile Indepen-
dent of IgV Mutations. To determine whether M- and
UM-CLLs are phenotypically different, we first analyzed
their gene expression profiles by two independent unsuper-
vised methods. When analyzed using Genes@Work (not
shown) or clustering by the average-linkage method (Fig.
1), CLLs displayed a common profile that is clearly distin-
guishable from that of FL (see first branching in the den-
drogram; Fig. 1). Purified and nonpurified cases were
readily recognized as different (second branching; Fig. 1),
most likely reflecting the contribution of normal cells con-
taminating the nonpurified cases. However, in both sub-
groups, M- and UM-CLLs were not distinguishable and
appear intermingled (Fig. 1). Lowering the “stringency” of
the analysis to the lowest limits of statistical significance for
pattern discovery, or varying the selection criteria for the
genes used in clustering (see Materials and Methods), did
not lead to further separation of M- and UM-cases (data
not shown). These results indicate that M- and UM-CLLs
have a common pattern of expression for most of the
12,000 genes analyzed, suggesting that they have a largely
common phenotype.
A Small Subset of Differentially Expressed Genes Allows the
Classification of M- and UM-CLLs. Subtle differences in
gene expression among closely related cell populations may
escape detection using unsupervised clustering analyses.
Thus, to determine whether M- and UM-CLLs have sub-
tle differences in gene expression, the two subgroups were
compared by supervised clustering using Genes@Work.
We first compared a set of 20 cases including nine UM-
and 11 M-CLL. To avoid the influence of contaminating
cells and to obtain the maximum specificity for the CLL
phenotype, these cases were selected among the purified
ones. Fig. 2 A shows that a set of 23 genes is differentially
expressed in M- versus UM-CLLs, the majority of them
(20 of 23) being upregulated in UM-CLLs versus M-CLLs.
Several of these genes are of unknown function, while the
remaining ones encode products of heterogeneous nature.
To validate the specificity of this differential gene ex-
pression profile, we tested whether it could be used to
classify an independent panel of 14 cases into M- and
UM-CLLs. To test the sensitivity of the classifier and its
potential clinical use, unpurified cases were used for this
analysis. Fig. 2 B shows that the profile shown in Fig. 2 A
could correctly classify all seven M-CLLs, and 5 of 7 UM-
CLLs (p-value of   0.025). Thus, the 23 genes differen-
tially expressed in M- versus UM-CLL represent a consis-
tent phenotypic difference between the two subgroups
(see Discussion).
Figure 1. M- and UM-CLLs share a common gene expression profile.
Dendrogram and matrix showing the hierarchical clustering of 2337 se-
lected genes (see Methods) of gene expression data generated from 34
CLL (“P” indicates purified cases) and six purified FL samples. The hier-
archical clustering algorithm used is based on the average-linkage method
(references 21 and 22). FL, M- and UM-CLL samples are coded by red,
blue, and green respectively. The matrix below the dendrogram depicts
the gene expression values of the individual samples, with columns repre-
senting individual tumor samples and rows representing individual genes
ordered according to hierarchical clustering. The color scale identifies rel-
ative gene expression changes normalized by the SD, with 0 representing
the mean expression level of a given gene across the panel.1630 Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia
The Gene Expression Profile of CLL Is Related to Memory B
Cells. Phenotypic as well as IgV gene analyses could not
conclusively identify the cell of origin of CLL. To address
this issue, we compared the gene expression profiles of
CLL to those of the major human B cell subsets, namely
GC CD77  (CBs) and CD77— (CCs) B cells, pre-GC (na-
ive) and post-GC (memory) B cells (16–19), as well
as GC-independent CD5-positive B cells. GC, naive
(IgD CD27 ), and memory (CD27 ) B cells were purified
by magnetic cell separation from tonsillar mononuclear
cells, while CD5  B cells were isolated from umbilical cord
blood (see Materials and Methods). Each B cell subset was
isolated from five individuals, and cRNA generated from
these fractions was hybridized to the U95A array as de-
scribed previously.
To determine whether CLLs are more related to GC
(CBs and CCs) or nonGC (naive and memory) B cells, we
first compared the CLL profiles to those differentially ex-
pressed by these two B cell subgroups (Fig. 3 A). Genes
that distinguish CB and CC cells from naive and memory
B cells as identified by supervised clustering are shown in
the left panel of Fig. 3 A, while the CLL samples are
aligned to the right to visualize the expression of the re-
spective genes in CLL cells. Genes known to be differen-
tially expressed among GC and nonGC B cells (CD10,
CD38, CD39, CD44, CD69, A-myb, Ki67, Bcl-6, Bcl-2)
(25–29) are indicated as internal controls. Fig. 3 A (right)
shows that the gene expression profile of CLL is signifi-
cantly more related to that of the nonGC naive and mem-
ory B cells (see Fig. 3 D for statistical analysis). The same
approach showed that the gene expression profile of CLL is
more related to naive and memory cells than to CD5  B
cells (Fig. 3 B and D). Analogous results were obtained us-
ing the less sensitive unsupervised clustering by the aver-
age-linkage method (data not shown). Finally, when CLLs
were compared with naive versus memory B cells (Fig. 3
C), the results showed that 14 of the 20 CLLs were signifi-
cantly more related to memory than to naive B cells (p-
value of  0.025). Note that, although less clear-cut than in
the previous comparative analysis (Fig. 3 A and B), the re-
Figure 2. Identification of genes differentially ex-
pressed in M- and UM-CLLs. (A) Supervised cluster
analysis of M- and UM-CLLs. Eight purified M- and
eight purified UM-CLL samples were examined by su-
pervised clustering using Genes@Work (references 23
and 24). Columns represent individual CLL samples,
rows correspond to genes. Color changes within a row indicate expression levels relative to the average of the sample population. Values are quantified
by the scale bar that visualizes the difference in the  ge score relative to the mean (0). Genes are ranked as described in the matrix description section. The
support value for supervised analysis was chosen as n   n0 – 2, where n0 is the number of cells in the phenotype set, allowing for up to two unclustered
cells per pattern in the phenotype set. Gene names and fold change are indicated; for GenBank accession no., see Supplementary Table I. Note that one
of the discriminating genes is a IgV region (V4–31) that is not expressed in the CLL cases; this is due to the fact that: errors are expected for mutated IgV
genes since single base pair variations affect the hybridization to oligonucleotides in the chip leading to misidentification of the IgV family member. (B)
The gene expression profiles distinguishing M- from UM-CLL (classifier) can predict the M- versus UM- status of an independent panel of unpurified
CLL. The classifier (23 genes; A) was applied to score 14 unpurified CLL cases (Table I), each identified by an open circle. The number of IgV gene mu-
tations of each case is indicated within the open circle. The relatedness of each of the test samples to the two CLL subgroups is indicated by their prox-
imity to either subgroup on the vertical axis (p-values are shown). The gray area marks the 95% confidence region, i.e. any sample with a score beyond
this range can be assigned to one of the CLL subgroups with  95% confidence (see Materials and Methods). Supplemental table available at http://
www.jem.org/cgi/content/full/194/11/1625/F2/DC1.1631 Klein et al.
latedness to memory B cells is significant considering that
memory and naive B cells differ in the expression of only
 140 of 12,000 genes (data not shown). While the differ-
ence was not statistically significant for the remaining six
cases, none of the CLL cases was more related to naive than
to memory B cells. The degree of relatedness to memory B
cells was not significantly different for M- and UM-CLLs.
Taken together, these results indicate that, independently
of their IgV mutational status, CLLs are more related to
memory cells than to naive, GC, or CD5  B cells.
This observation prompted a direct analysis of the differ-
ences in gene expression profiles between CLL and mem-
ory B cells by supervised clustering. Fig. 4 shows the results
of this analysis with the differentially expressed genes orga-
nized according to putative functional categories, including
proliferation, apoptosis, cytokines/chemokines and recep-
tors, adhesion, and cytokinesis. A number of proliferation-
associated genes were downregulated in CLL cells (e.g.,
c-Myc, average fold difference in expression levels [CLL
versus memory cells], ninefold; cyclin B, 13-fold; and E2-C,
80-fold). Apoptotic functions appear to be suppressed in
CLL with the antiapoptotic gene Bcl-2 upregulated (four-
fold) as expected (1), and various genes encoding proapop-
totic molecules uniformly downregulated (BID, 33-fold;
Rad9 [reference 30], ninefold; DRAK1 [reference 31],
threefold; and DRAK2 [reference 31], fourfold). The IL-4
pathway appears to be activated in CLL, based on the ob-
served previously (32) upregulated expression of the gene
encoding the IL-4-receptor (sixfold), on the observed
downregulation of SOCS-1 (Fig. 4), an inhibitor of the IL-
4-signaling pathway (33) (19-fold), and consistent with the
fact that CLL cells are responsive to IL-4 in vitro (1) (see
Discussion). Finally, the expression of various genes encod-
ing adhesion-associated molecules appears differentially
regulated in CLL compared with memory B cells. Overall,
these results indicate that CLL differs from memory B cells
in the expression of numerous genes that suggest a more
quiescent, antiapoptotic phenotype, with distinct cytokine
and chemokine response and adhesion properties.
Identification of Genes Specifically Expressed in CLL. To
identify genes specifically up or downregulated in CLL
cells, we used supervised clustering to compare the gene
expression profiles of CLL cases to those of normal B cell
subsets (naive, CBs, CCs, memory) and to those derived
from various nonHodgkin lymphoma subtypes, including
FL, DLCL, and BL. Fig. 5 indicates that 32 genes are spe-
cifically expressed (or overexpressed), while  50 genes ap-
pear downregulated in CLL. Several of the genes upregu-
lated in CLL are involved in signal transduction pathways:
CDC25 (average difference in expression level [CLL versus
all others]: 14-fold over background) is a Ras guanine nu-
cleotide exchange factor (34, 35). EPAC (35-fold over
background) plays a role in the cAMP signal transduction
pathway via Rap1 (36), a Ras-related guanine nucleotide
exchange factor involved in B cell receptor signaling and
oncogenesis (see Discussion). Significantly overexpressed
genes include also: (i) the cell surface receptors Ror1 (19-
fold), an orphan tyrosine kinase receptor, and the throm-
boxane A2 receptor (fourfold); and (ii) several genes related
to TGF-  signaling, such as fibromodulin ( 250 fold over
background), associated with modulation of TGF-  signal-
ing and cell adhesion (37), the TGF- –inducible TIEG2, a
SP1-like transcription factor (38) (10-fold over back-
ground), and BIGH3/TGFB1 (39) (38-fold). Genes specif-
ically downregulated in CLL include genes involved in cell
cycle progression and DNA replication and metabolism
(E2-C, CIP2/KAP, CDC2, cyclin B, ribonucleotide re-
ductase, thymidine kinase, dihydrofolate reductase, topo-
isomerase IIa), suggesting a markedly quiescent phenotype.
Discussion
Gene expression profiling allows a more comprehensive
examination of cell phenotypes than the ones based on the
analysis of individual or small numbers of genes, proteins,
or signaling pathways. This technology has been used in
this study to address three open questions regarding CLL:
does CLL include one or two biological phenotypes since
it displays a discordant IgV mutational status and clinical
behavior? What is the cellular origin of CLL within the B
cell lineage? Can a CLL-specific gene expression profile be
identified? The results obtained directly address these ques-
tions and have implications relevant for the pathogenesis
and, possibly, for the clinical management of this disease.
CLLs Display a Common Phenotype Independent of IgV
Mutations. The gene expression profiles shown in Fig. 1
demonstrate that CLL has a characteristic gene expression
profile that is clearly distinguishable from FL, a malignancy
derived from mature B cells and displaying an indolent
clinical course similar to CLL. This observation confirms
the results obtained by Alizadeh et al. using a different DNA
microarray technology (oligonucleotide versus cDNA-
based arrays) and a only partially overlapping set of genes
examined (12,000 nonlymphocyte-biased versus 18,000
lymphocyte-biased; reference 40).
These results also show that CLLs have a homogeneous
phenotype independent of the presence of IgV mutations.
This phenotype is defined by the common pattern of ex-
pression of 12,000 genes, with only 23 being differentially
expressed in the M- versus UM-subtypes. Although signif-
icant differences in protein expression or modification
cannot be excluded by gene expression profiling, this re-
sult does not support the hypothesis that CLL may include
distinct biological entities (8, 13), as it is the case, for in-
stance, for DLCL (40). Rather, these findings strongly
suggest that all CLLs may derive from a common cell pre-
cursor through a common pathogenetic mechanism (see
below).
CLLs Are Related to Memory B Cells. Based on various
phenotypic similarities, mainly the presence of the CD5
marker and on initial reports that CLL displayed unmutated
IgV, it has long been proposed that CLL may derive from
the malignant transformation of CD5  B cells (4), the hu-
man equivalent of mouse B1 cells. Subsequently, the iden-
tification of M-CLLs led to the hypothesis that a fraction of
CLL cases may derive from a GC-experienced B cell, pos-1632 Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia
sibly a memory B cell (8, 9, 13). The gene expression pro-
files shown here suggest that CLL do not derive from
CD5  B cells or from GC B cells, while they indicate that
both M- and UM-CLLs are more related to memory than
to naive B cells. This conclusion is based on a comparative
evaluation and cannot formally exclude the existence of a
presently unrecognized B cell subpopulation that is more
similar to CLL than memory B cells. However, this con-
clusion is in agreement with other well established traits
shared by CLL and memory B cells, namely the frequent
presence of IgV mutations and, most notable, the expres-
sion of the CD27 marker (14, 17–19, 41). The fact that
CLL cells express the CD5 and CD23 markers, which are
not typical of memory B cells, is not inconsistent with their
derivation from memory B cells since the expression of
these markers could represent an abnormal trait of the
transformed phenotype rather than a characteristic of the
normal precursor of CLL. In the case of CD23, whose ex-
pression is induced by IL-4 (42), this hypothesis is sup-
ported by the abnormal expression of several genes in-
volved in the IL-4 pathway (upregulation of IL-4 receptor,
downregulation of SOCS1; see Results) and by the abnor-
mal sensitivity of CLL to IL-4 in vitro (1). Finally, a deriva-
tion of CLL cells from memory B cells is also consistent
Figure 3. The gene expression profile of CLL is related to that of mem-
ory B cells. Gene expression data sets generated from 20 purified CLL cases
are compared with the genes differentially expressed between CB/CC and
memory/naive B cells (A), memory/naive B cells vs. CD5  cells (B), and
memory versus naive B cells (C). Genes differentially expressed between
the various B cell subpopulations were identified by supervised clustering using Genes@Work. Matrices (a–c) and gene ranking are as in Fig. 2. Genes
known to be differentially expressed among GC and nonGC B-cells and among naive and memory B cells, or on CLL cells (IL-4R), are indicated (refer-
ences 19, 25–29). D shows the quantitative relatedness of the CLLs to the normal B cell populations as derived from panels A–C as described for Fig. 2
B. The gray area marks the 95% confidence region; the lower and upper margins of the gray area each correspond to a p-value of 0.025 (p-values decrease
with increasing distance from the x-axis). Open and closed circles represent M- and UM-CLL cases, respectively.1633 Klein et al.
with the fact that CLLs lack chromosomal translocations
which are thought to occur in developing B cells rearrang-
ing their antigen receptors or in GC B cells (see below).
The notion that CLL may all derive from memory B
cells leaves open the question of why a sizable fraction of
them expresses unmutated IgV genes, which are typical for
pre-GC, naive B cells, or GC-independent cells involved
in T cell–independent humoral responses. One possible ex-
planation is provided by the observation that a minor frac-
tion of CD27  B cells carry unmutated IgV (17, 18) and
may have entered the memory cell pool without acquiring
IgV mutations, possibly due to already high affinity for the
antigen. Such CD27  unmutated memory B cells may
therefore represent the normal counterpart of UM-CLLs.
Alternatively, the precursor of UM-CLLs may be a cell that
has acquired a memory phenotype via encounter with a
T-independent (and thus GC-independent and IgV muta-
tion-independent) pathway (9). This hypothesis implies
that the antigen recognized by M-CLLs and UM-CLLs
may be of different nature, consistent also with the obser-
vation that CDRIII length and IgV region usage differs
among the two subgroups (9, 43). A difference in the na-
ture and/or time of exposure to antigen may also explain
the different clinical behavior of the two subgroups.
Overall, the finding that CLLs, including the UM sub-
type, display a gene expression profile similar to memory B
cells warrants further investigations on the possible hetero-
geneity of the memory B cell pool (44, 45). The few genes
that are differentially expressed in M- versus UM-CLLs
(Fig. 2 A) may turn useful in dissecting this heterogeneity,
although further characterization is needed because they
represent a heterogeneous group of genes, some of un-
known function.
Implications for CLL Pathogenesis. The observation that
all CLLs share a common gene expression profile suggests
that they derive from a common pathogenetic pathway.
This notion is consistent with the relatively homogeneous
cytogenetic profile of CLL, characterized by few common
chromosomal abnormalities and, particularly, by the strong
association with 13q14 deletions, present in the majority of
cases (up to 70%) (46–48). These deletions are often
present as a single chromosomal abnormality and are
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thought to reflect the loss or inactivation of a still unknown
tumor suppressor gene (46–48). The homogeneity of the
gene expression profile of CLL suggests that this alteration
or some functional equivalent (e.g., inactivating point mu-
tations) may be present also in those cases lacking cytoge-
netically or molecularly detectable 13q14 deletions.
The observation that CLL is more related to memory B
cells than to any other known normal B cell subset suggests
that the multistep process leading to CLL may actually ini-
tiate in memory B cells. This hypothesis is consistent with
the notion that, unique among lymphoid malignancies,
CLL lack reciprocal balanced chromosomal translocations
(2). These aberrations are thought to occur either during Ig
VDJ recombination in maturing B cells, or during Ig hy-
permutation and isotype switch in mature B cells within
the GC (11), and, accordingly, are common in B cell lym-
phoma, most of which derive from mature GC B cells (12,
49). Thus, if the transformation process leading to CLL ini-
tiates in memory B cells, it cannot involve chromosomal
translocations since the mechanisms involved in these aber-
rations have been inactivated in these cells. This notion is
consistent with the predominant presence in CLL of ge-
netic alterations, such as deletions and amplifications, com-
mon in tumors deriving from tissues not physiologically
subjected to antigen receptor gene rearrangements or hy-
permutation (50).
The comparative analysis of the gene expression profiles
of CLL versus memory B cells (Fig. 4) or other normal and
Figure 4. Identification of
genes specifically expressed in
CLLs vs. memory B cells. Gene
expression profiles of 10 ran-
domly selected purified CLL
cases (five UM- and five M-CLL,
respectively) were compared
with those of five memory cell
preparations by supervised clus-
tering using Genes@Work. Ma-
trices and gene ranking are as in
Fig. 2; the fold change is indi-
cated. For GenBank accession
no., see Supplementary Table II
Genes are grouped according to
putative functional categories
and ranked within each category.
CD5 and CD23 are indicated as
internal controls. Supplemental
table available at http://
www.jem.org/cgi/content/full/
194/11/1625/F4/DC1.1635 Klein et al.
neoplastic cells (Fig. 5) provides a significant body of new
information to dissect the CLL phenotype. First, the
downregulation of a number of proapoptotic genes, to-
gether with the already known upregulation of the antiap-
optotic molecule Bcl-2, is consistent with the documented
long-lived apoptosis-resistant phenotype of CLL (1). Sec-
ond, unique among normal and neoplastic B cells, CLL
cells consistently display a significant overexpression of the
EPAC and CDC25 genes, both encoding guanine nucle-
otide exchange factors that activate, respectively, Rap1 and
Ras, the small GTPases that control pleiotropic transcrip-
tional responses via the Raf/ERK pathway (51). This ob-
servation has possible pathogenetic relevance and warrants
further studies since deregulation of the Ras pathway rep-
resents one of the most common alterations in human tu-
mors (52), while recent evidence suggests that Rap1 can be
deregulated by chromosomal translocations in lymphoid
malignancy (53). Finally, the upregulation of mRNA for
several cytokine or chemokine receptors compared with
memory cells (IL-4R, TGF-  type III receptor, CCR7;
Fig. 4) or to other B cells (Ror1 and thromboxane A2 re-
ceptor; Fig. 5) suggests that CLL cells may be abnormally
responsive to certain stimuli. While each of the genes spe-
cifically expressed in CLL requires validation for differential
Figure 5. Identification of genes
specifically expressed in CLL. Gene
expression profiles of 10 randomly
selected purified CLL cases (five
UM- and five M-CLL, respectively)
were compared with those generated
from normal (CBs, CCs, naive, and
memory) B cell subpopulations, pu-
rified nonHodgkin lymphoma cells
(DLCL, BL, and FL), and DLCL and
BL cell lines by supervised clustering
using Genes@Work. Matrices and
gene ranking are as in Fig. 2. Genes
and fold change are indicated at the
right; for GenBank accession no., see
Supplementary Table III. Supple-
mental table available at http://
www.jem.org/cgi/content/full/194/
11/1625/F5/DC1.1636 Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia
expression at the protein level, these observations are po-
tentially important for CLL pathogenesis and are amenable
to experimental testing.
Clinical Implications. The results of these studies have
potential clinical application in several areas. First, the abil-
ity to distinguish M- versus UM-CLLs by gene expression
profiling (Fig. 2) represents a potential prognostic test for
CLL since these two groups have a distinct clinical course.
It is unlikely that this analysis will find clinical application
using expensive microarrays with 12,000 genes such as the
ones used in this study since IgV sequencing is more rapid
and economical. Rather, these results should lead to the
development of simple and inexpensive cytochemical assays
recognizing the products of few of the genes differentially
expressed in M- versus UM-CLLs. Second, the products of
genes specifically expressed in CLL (Fig. 5) represent po-
tential markers for the diagnosis of CLL, its differential di-
agnosis from related B cell malignancies, or the detection of
small numbers of CLL cells in minimal residual disease con-
texts. Finally, the products of these same genes represent
potential therapeutic targets based on their specific expres-
sion in CLL cells versus normal cells. The successful use of
mAb therapy targeting the CD20 molecule in B cell lym-
phoma (54) suggests that cell surface receptors that are ab-
normally expressed in CLL (e.g., Ror1 and thromboxane
A2 receptors) may represent good candidates for initial test-
ing of this approach. Further DNA microarray studies may
be aimed at determining the expression profiles of cytoge-
netically distinct CLL cases or cases displaying different
clinical behavior (55).
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